Extended Data Figure 7 : Blockade of CEACAM1 and TIM-3 or genetic loss of CEACAM1 increases anti-tumour immunity.

From: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

Extended Data Figure 7

a, Schematic presentation of antibody blockade protocol described in Fig. 4g. b, Schematic presentation of antibody blockade protocol referred to in panel c. c, Prevention of CT26 tumour growth with indicated combinations of antibodies as in (b) (n = 5 per group, post-hoc Dunnett’s correction followed by Friedman test). d, Schematic of schedule used for therapeutic antibody administration as described in e. e, Synergy of CEACAM1 and programmed death-ligand 1 (PD-L1) blockade in a therapeutic protocol as described in d was performed in wild-type BALB/c mice that received a subcutaneous inoculation of CT26 tumour cells. Mean tumour size (n = 5 per group, with linear regression analysis). Note synergistic increase in anti-tumour effect when CEACAM1 and PD-L1 co-blockade was performed. f, TILs were analysed for the relative proportion of CD4+ T cells that produced IL-10 as in Fig. 4g (n = 4, unpaired Student’s t-test with Mann–Whitney U correction). g, Percentages of CD8+ T cells from spleen show that antibody treatments have no effects on total CD8+ T cell numbers (n = 7/8, unpaired two-tailed t-test). h, Negative correlation of the numbers of AH1 tet+ CD8+ T cells and the size of tumours in the draining lymph nodes from the tumour-bearing mice in Fig. 4g (Pearson’s correlation coefficient, r = 0.9560, P = 0.044). i, Representative flow cytometry for tumour-specific (AH1-tetramer, tet+) CD8+ T cells in draining lymph nodes of mice from the indicated genotypes. Data are mean ± s.e.m. and represent three (fi), two (e) and one (c) independent experiments. *P < 0.05; ***P < 0.001.